John B Buse MD
Diabetes, Obesity
Professor of Medicine, University of North Carolina School of Medicine
Join to view full profile
100 Eastowne DrPod 3BChapel Hill, NC 27514
Phone+1 984-974-2950
Fax+1 984-974-2924
Dr. Buse is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Diabetes mellitus
Education & Training
University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1992- University of ChicagoResidency, Internal Medicine, 1986 - 1988
Duke UniversityPh.D., Physiology/Immunology, 1979 - 1986
Duke University School of MedicineClass of 1986- Dartmouth CollegeAB, Biochemistry, Cum Laude, 1976 - 1979
Certifications & Licensure
NC State Medical License 1994 - 2027
IL State Medical License 1986 - 1996
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Best Doctors Best Doctors
- America's Top Doctors Castle Connolly, 2010-2019
- �Highly Cited Researchers� in �Clinical Medicine� Thomson Reuters, 2014-2018
Clinical Trials
Publications & Presentations
PubMed
- Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Melanie J Davies, Vanita R Aroda, Mandeep Bajaj, Nuha A ElSayed, Francesco Giorgino
Diabetologia. 2026-10-02 - Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Melanie J Davies, Vanita R Aroda, Mandeep Bajaj, Nuha A ElSayed, Francesco Giorgino
Diabetes Care. 2026-10-02 - Disentangling Sex Differences in Sulfonylurea Drug Response With Genome-Wide Association Studies in Individuals With Type 2 Diabetes.Joseph H Breeyear, John S House, Mark Kvale, Stella Nam, Farida S Akhtari
Clinical Pharmacology and Therapeutics. 2026-10-01
Journal Articles
- Improved Time in Range and Glycemic Variability with Sotagliflozin in Combination with Insulin in Adults with Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous ...Jake A Kushner, John B Buse, Satish K Garg, Darren K McGuire, Diabetes Care
- Lower Rates of Cardiovascular Events and Mortality Associated with Liraglutide Use in Patients Treated with Basal Insulin – A DEVOTE Subanalysis (DEVOTE 10)John B Buse, Darren K McGuire, Richard E Pratley, Diabetes, Obesity and Metabolism
- Proinsulin Secretion Is a Persistent Feature of Type 1 DiabetesSims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swense..., Diabetes Care, 1/1/2019
Books/Book Chapters
Lectures
- For Debate: A Reasonable A1C Goal for Many Nonpregnant Adults is <7% (53 mmol/mol)ENDO 2019 - New Orleans, LA - 3/23/2019
- Neoplasms Reported with Liraglutide or Placebo in People with Type 2 Diabetes: Results from the LEADER Randomized TrialChapel Hill, NC - 6/15/2014
- Duke Regional Diabetes Symposium 2012Duke University School of Medicine, Kannapolis, North Carolina - 7/13/2012
Other
- Consensus Development Conference on Pramlintide in the Management of Type 1 and Type 2 DiabetesHirsch IB, Blonde L, Buse J, Close K, Edelman SV, Peters A, Valentine V, Wysham C, Garg S, The Diabetes Education Group
Lakeville, CT - 1/1/2006 - A practical approach to the management of type 2 diabetes in the context of cardiovascular risk.Buse JB, Henry RR, Pri-Med in Practice
Boston, MA - 1/1/2006 - Management of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in Adults.JB Buse, M Menke, TS Sisca, Scherer Clinical Communication
1/1/2005
Authored Content
- Management of Type 1 Diabetes with a Very Low–Carbohydrate Diet: A Word of CautionAugust 2018
Press Mentions
20 Years Later, ‘A Tremendous Amount Going On’ in Management of Cardiometabolic DiseaseOctober 29th, 2025- Doctors: NC Made the Wrong Decision About Weight Loss Medication Coverage | OpinionOctober 27th, 2025
- FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 DiabetesOctober 22nd, 2025
Grant Support
- Genome-Wide Association Study Of Accord Lipid TrialNational Heart, Lung, And Blood Institute2012
- Clinical Trial: Action To Control Cardiovascular Risk In Diabetes Trial (ACCORD)National Center For Research Resources2008
- NMR &Chemical Lipid Analysis In Patients With Type 2 DiabetesNational Center For Research Resources2007
- Action To Control Cardiovascular Risk In Diabetes Trial (ACCORD)National Center For Research Resources2007
- Zenarestat (Ci 1014) In Treatment Of Diabetic NeuropathyNational Center For Research Resources1999–2002
Committees
- Co-chair, member, CTSA Program Steering Committee 2018 - Present
Research History
- Director, Diabetes CenterOur group’s research efforts focus in clinical trials, epidemiology and translational efforts towards application of novel ideas to clinical practice.1994 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: